DEF: Retractable Technologies Sets 2026 Annual Meeting, Director Elections

Retractable Technologies, Inc. announced its 2026 Annual Meeting of Shareholders to elect three Class 2 Directors and provided updates on corporate governance, executive compensation, and related party transactions.

Summary

• The company will hold its 2026 virtual Annual Meeting of Shareholders on May 8, 2026, at 10:00 a.m. Central time, to vote on the election of three Class 2 Directors.
• The Board of Directors recommends voting 'For All' the nominated Class 2 Directors: Thomas J. Shaw, Walter O. Bigby, Jr., and John W. Fort III.
• Thomas J. Shaw, the founder, Chairman, President, and CEO, holds 55.7% beneficial ownership of the company's common stock as of March 9, 2026.
• Executive compensation is primarily based on base salary, with cash bonuses granted discretionarily, and no current policies directly link compensation to specific financial measures.
• Royalties of $3,154,263 in 2025 and $3,506,716 in 2024 were paid to Thomas J. Shaw under a 1995 Technology Licensing Agreement.
• The company reported net losses of $(12,565,230) in 2025, $(11,886,524) in 2024, and $(7,011,036) in 2023, a significant decline from net income of $56,064,241 in 2021.
• Executive stock options granted in 2021 were terminated in December 2022 because they were 'significantly underwater' and no longer likely to reward officers as intended.
• The ratio of the company's median employee annual total compensation ($37,458) to the principal executive officer's total compensation ($1,222,045) was 1:32.34 in 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a negative sentiment due to the consistent and increasing net losses over the past three years, significant underperformance compared to its industry peer group, and the termination of executive stock options due to being underwater, all of which point to operational and market challenges.

Positives

• Over half of the Board of Directors are independent, enhancing oversight and governance.
• The company maintains established standing Audit, Compensation and Benefits, and Nominating Committees, each with a written charter.
• A Code of Business Conduct and Ethics is in place, prohibiting short sales, derivatives, and hedging transactions by employees and directors.
• Shareholders have consistently voted in favor of executive compensation proposals and the triennial frequency of advisory votes.
• Thomas J. Shaw, as founder and primary inventor, possesses deep knowledge of the company's products and operations, which is vital for strategic supervision.

Negatives

• The company has experienced increasing net losses for the past three fiscal years, reaching $(12,565,230) in 2025.
• Executive stock options granted in 2021 were terminated in December 2022 because they were 'significantly underwater,' indicating poor stock performance.
• There are currently no policies linking executive compensation to the attainment of specific financial measures, despite a clawback policy for restatements.
• The company's shareholder return has significantly underperformed its peer group (Dow Jones US Select Medical Equipment Index) in recent years.
• Thomas J. Shaw's majority beneficial ownership means his vote is often determinative in shareholder matters, potentially limiting other shareholder influence.

Risks

• The company operates in an 'anticompetitive environment' where its ability to grow has been constrained by larger market players.
• Periods of 'reduced liquidity' are considered when evaluating potential salary reductions, indicating financial strain.
• Significant reliance on Thomas J. Shaw as the primary inventor and CEO, whose deep knowledge is considered 'vital' to the company's supervision and product development.

Future Outlook

The company's design team, led by Thomas J. Shaw, continues product development of other medical safety devices utilizing patented friction ring technology. The terms for Class 2 Directors, if elected, will extend until the 2028 annual meeting.

Management Comments

• "Our ability to grow has been constrained by larger market players."
• "We do not believe our stock price adequately reflects our performance."

Industry Context

StockSavvy.ai notes that the company operates in the medical safety devices sector, a market often characterized by intense competition and regulatory scrutiny. The company's stated challenge of being "constrained by larger market players" suggests a competitive landscape dominated by established industry giants, which can hinder growth for smaller innovators.

Comparison to Industry Standards

• StockSavvy.ai observes that the company's recent trend of increasing net losses, culminating in a $(12.57) million loss in 2025, contrasts sharply with the generally positive shareholder returns of the Dow Jones US Select Medical Equipment Index (DJSMDQ) peer group, which saw returns of 114.94% in 2025.
• While the company's own shareholder return was 7.17% in 2025, this significantly underperformed the DJSMDQ peer group, indicating a disconnect between company performance and broader industry trends.
• The termination of executive stock options in 2022 due to being 'significantly underwater' further highlights a potential underperformance relative to market expectations and industry benchmarks for executive incentive effectiveness.

Corporate Governance

Legal Proceedings

• The Board reviews 'ongoing litigation' as one of the principal factors influencing operating results at every regular quarterly meeting, indicating potential legal matters, though no specific details are provided.

Related Party Transactions

• Thomas J. Shaw, the company's founder, Chairman, President, CEO, and a shareholder holding more than 5% of outstanding common stock, has a Technology Licensing Agreement from 1995.
• Under this agreement, Mr. Shaw receives a royalty of 5% of gross sales of all licensed retractable medical safety products sold worldwide.
• Royalties paid to Mr. Shaw were $3,154,263 in 2025 and $3,506,716 in 2024.
• If the company sublicenses the technology and the sublicensees' customers are not known to the company, Mr. Shaw is entitled to 50% of the royalties actually paid to the company by such sublicensee.

Stakeholder Impact

• Shareholders are asked to vote on the election of directors and are impacted by the company's declining financial performance and the CEO's majority voting control.
• Employees, including executive officers, participate in a 401(k) plan with company matching contributions, and their compensation structure emphasizes base salary due to market constraints.
• Customers benefit from the ongoing product development of medical safety devices, led by Thomas J. Shaw.
• Management, particularly the CEO, benefits from an employment agreement that includes a substantial annual salary and significant termination benefits, even amidst company losses.

Next Steps

• Shareholders are invited to attend the virtual Annual Meeting on May 8, 2026, to vote on the election of three Class 2 Directors.
• Class 2 Directors, if elected, will hold office until the 2028 annual meeting, or upon their earlier retirement, resignation, or removal.
• Shareholders wishing to submit proposals for inclusion in the 2027 Annual Meeting proxy statement must do so by November 27, 2026.
• Shareholders intending to propose other business for the 2027 Annual Meeting must provide written notice by February 10, 2027.
• Shareholders intending to solicit proxies for director nominees for the 2027 Annual Meeting must provide notice by March 9, 2027.

Key Dates

Recommendation

The company has demonstrated a concerning trend of increasing net losses over the past three fiscal years, culminating in a substantial loss in 2025. Its shareholder returns have significantly lagged behind its industry peer group, indicating fundamental underperformance. The termination of executive stock options due to being 'significantly underwater' further underscores a lack of value creation. While the company has a strong corporate governance framework and a founder with deep product knowledge, the financial trajectory and the disconnect between executive compensation and financial performance suggest significant challenges that warrant a 'sell' recommendation for seasoned investors.

Keywords

Retractable Technologies, RVP, Proxy Statement, Annual Meeting, Director Election, Corporate Governance, Executive Compensation, SEC Filing, Medical Safety Devices, Shareholder Vote, Related Party Transaction, Financial Performance, Net Loss